PCO371 ( DrugBank: PCO-371 )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 235 | 副甲状腺機能低下症 | 1 |
235. 副甲状腺機能低下症
臨床試験数 : 88 / 薬物数 : 128 - (DrugBank : 25) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04209179 (ClinicalTrials.gov) | July 23, 2020 | 28/11/2019 | A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism | A Randomized, Double-Blind, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PCO371 in Patients With Hypoparathyroidism | Hypoparathyroidism | Drug: PCO371;Drug: Placebo | Chugai Pharmaceutical | NULL | Terminated | 18 Years | N/A | All | 5 | Phase 1 | United States;Canada;Hungary |